Structure Therapeutics Inc. (GPCR) Stock: Skyrockets After Positive Obesity Trial Result
GPCR Phase 2 Breakthrough shows major weight loss results, pushing stock up 99% and spotlighting a strong new oral GLP-1 contender.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Structure Therapeutics Inc. (GPCR) Stock: Skyrockets After Positive Obesity Trial Result
GPCR Phase 2 Breakthrough shows major weight loss results, pushing stock up 99% and spotlighting a strong new oral GLP-1 contender.